Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease

Complexa Names Elisabeth Leiderman, MD, MBA, Chief Business Officer

Complexa Receives Orphan Drug Designation from the FDA for CXA-10 in Pulmonary Arterial Hypertension

Complexa Names Theodore Danoff, MD, PhD, Chief Medical Officer

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension

Complexa Presents Data Evaluating the Pharmacological Action of CXA-10 on Drug-metabolizing Transport Proteins at 2018 American College of Clinical Pharmacology Annual Meeting

Complexa Names William Leong, Vice President of Chemistry, Manufacturing and Controls

Complexa Announces Presentation of Phase 1 Data Evaluating Lead Candidate CXA-10 as a Disease-Modifying Therapy in Pulmonary Arterial Hypertension at PHA’s 2018 International PH Conference

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis